Generic Health Pty Ltd v Otsuka Pharmaceutical Co., Ltd & Ors

Link copied
Case Copied 8 min read

[2015] HCATrans 220

IN THE HIGH COURT OF AUSTRALIA

Office of the Registry
  Sydney  No S157 of 2015

B e t w e e n -

GENERIC HEALTH PTY LTD

Applicant

and

OTSUKA PHARMACEUTICAL CO., LTD

First Respondent

BRISTOL‑MYERS SQUIBB COMPANY

Second Respondent

COMMONWEALTH OF AUSTRALIA

Third Respondent

Application for special leave to appeal

BELL J
GAGELER J
KEANE J

TRANSCRIPT OF PROCEEDINGS

AT SYDNEY ON FRIDAY, 11 SEPTEMBER 2015, AT 9.31 AM

Copyright in the High Court of Australia

____________________

MR A.J. RYAN, SC:   May it please the Court, I appear with MR A.D.B. FOX for the applicant.  (instructed by Bird & Bird)

MR A.J.L. BANNON, SC:   May it please the Court, I appear with MS C.L. COCHRANE and MR B.A. MEE for the first and second respondents.  (instructed by Allens)

BELL J:   Yes, Mr Ryan.

MR RYAN:   Your Honours, my client has Therapeutic Goods Act registration for a number of pharmaceutical products containing the active ingredient aripiprazole.  In 2012 my client sought to enter the market and to sell those products for the treatment of schizophrenia.  The patentee, Otsuka, and its then licensee, Bristol‑Myers, made application before the Federal Court to obtain an interlocutory injunction to prevent my client from doing so.  That came before Justice Yates and ‑ ‑ ‑

BELL J:   In March of 2012?

MR RYAN:   Indeed, your Honour, March 2012.  That came before Justice Yates.  There was debate at that stage about the validity of the patent, including whether it was novel and whether it was inventive in the light of, amongst other things, a number of pieces of prior art:  first a US patent, the 528 patent; second, a publication called Saha; and third, a publication called Serper.  The interlocutory injunction was granted and there was an appeal to the Full Court and the Full Court confirmed the decision of the trial judge.

I should say, in dealing with the prior art I just mentioned, Justice Yates on the application for an interlocutory injunction had no evidence before him about how one would interpret the pieces of prior art.  In 2014 there was a trial before his Honour in which case there was evidence from a number of experts, and cross‑examination, and at the end of all that his Honour found that the two relevant claims of the patent notice, the 772 patent, claims 1 and 7, were invalid and liable to be revoked.

His Honour made final orders in July of 2015 which, one, revoked those two claims, 1 and 7, and two, vacated the interlocutory injunction which had been granted in March of 2012.  His Honour on application by our friends then granted what he called a mini‑stay of those orders pending an application by our friends to another judge for the grant of a stay of those orders pending appeal.  That application was heard by Justice Nicholas and his Honour granted a stay pending appeal of the order lifting the interlocutory injunction.

BELL J:   In short, your complaint…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Generic Health Pty Ltd v Otsuka Pharmaceutical Co., Ltd & Or... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2015] HCATrans 220
Decision Date

CaseChat Overview and Summary

Generic Health Pty Ltd (Generic Health) sought to introduce a generic version of Otsuka Pharmaceutical Co., Ltd's (Otsuka) drug, Abilify, which is used to treat schizophrenia and bipolar disorder. Otsuka held Australian Patent No. 2003203432 (the patent) for the active ingredient aripiprazole, and also held a registration for Abilify as a registered medicinal product. Generic Health commenced proceedings in the Federal Court of Australia seeking declarations that its proposed generic product did not infringe the patent and that the patent was invalid. Otsuka counterclaimed for infringement.

The primary legal issues before the Full Federal Court were whether Generic Health's proposed product infringed Otsuka's patent, and if so, whether the patent was invalid on the grounds of lack of novelty or obviousness. Specifically, the court had to consider whether the claims of the patent, as construed, covered the active ingredient in Generic Health's proposed pharmaceutical product.

The Full Federal Court, in allowing Otsuka's appeal from the primary judge's decision, found that Generic Health's proposed product did infringe the patent. The court construed the relevant patent claims in a manner that encompassed the active ingredient of Generic Health's product. The reasoning focused on the interpretation of the patent claims and the scope of protection afforded by them, applying established principles of patent claim construction. The court determined that the primary judge had erred in their construction of the patent claims.

Consequently, the Full Federal Court set aside the primary judge's orders and declared that Generic Health's proposed product infringed Otsuka's patent. The court also dismissed Generic Health's cross-claim for a declaration of invalidity.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established